The Future of Pediatric Oncology: ATR Inhibition and the Evolution of Hepatoblastoma Management

from TheBrief.Health · host TheBrief.Health

ATR inhibitors offer a promising targeted therapy for high-risk hepatoblastoma, exploiting tumor replication stress to improve survival while potentially reducing cisplatin-related toxicity and long-term harm.

Episode metadata supplied by the publisher feed · Published Feb 24, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

The Future of Pediatric Oncology: ATR Inhibition and the Evolution of Hepatoblastoma Management

0:00 1:35

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on February 24, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!